A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease

Janus kinase inhibitors (JAKi) are an exciting option for the treatment of rheumatoid arthritis (RA) but little is known about their safety and tolerability in patients with existing respiratory disorders. The objective was to compare pulmonary safety of JAKi versus rituximab in patients with concur...

Descripción completa

Detalles Bibliográficos
Autores principales: Cronin, Owen, McKnight, Olivia, Keir, Lindsay, Ralston, Stuart H., Hirani, Nikhil, Harris, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Observational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019418/
https://www.ncbi.nlm.nih.gov/pubmed/33721094
http://dx.doi.org/10.1007/s00296-021-04835-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019418/
https://www.ncbi.nlm.nih.gov/pubmed/33721094
http://dx.doi.org/10.1007/s00296-021-04835-1

Ejemplares similares